Medical University Graz Department of Oncology 8036 Graz AustriaRekrutierend» Google-Maps Ansprechpartner: Jakob Riedl, Dr. Dr. Phone: +43 316 385 31256 E-Mail: j.riedl@medunigraz.at
1. Proportion of patients with locally advanced inoperable and/or metastatic PDAC undergoing palliative second line therapy after progression on first line chemotherapy (Time Frame - 24 months)
Secondary outcome:
1. To identify prognostic and predictive features for treatment efficacy (Time Frame - 24 months)
2. To identify prognostic and predictive features for clinical outcome (Time Frame - 24 months)
3. To identify prognostic and predictive features for Neuropathy (Time Frame - 24 months): Relative frequency of Grade 3 and Grade 4 Adverse Events according to the Common Terminology Criteria of Adverse Events (CTCAE) will be documented
4. To identify prognostic and predictive features for Febrile Neuropathy (Time Frame - 24 months): Relative frequency of Grade 3 and Grade 4 Adverse Events (CTCAE) will be documented
5. To identify prognostic and predictive features for Thrombocytopenia (Time Frame - 24 months): Relative frequency of Grade 3 and Grade 4 Adverse Events (CTCAE) will be documented
6. To identify prognostic and predictive features for Anemia (Time Frame - 24 months): Relative frequency of Grade 3 and Grade 4 Adverse Events (CTCAE) will be documented
7. To identify prognostic and predictive features for Nausea/Vomiting (Time Frame - 24 months): Relative frequency of Grade 3 and Grade 4 Adverse Events (CTCAE) will be documented
8. To identify prognostic and predictive features for Skin toxicity (Time Frame - 24 months): Relative frequency of Grade 3 and Grade 4 Adverse Events (CTCAE) will be documented
9. To identify prognostic and predictive features for rash (Time Frame - 24 months): Relative frequency of Grade 3 and Grade 4 Adverse Events (CTCAE) will be documented
10. To identify prognostic and predictive features for mucositis (Time Frame - 24 months): Relative frequency of Grade 3 and Grade 4 Adverse Events (CTCAE) will be documented
11. To identify prognostic and predictive features for Fatigue (Time Frame - 24 months): Relative frequency of Grade 3 and Grade 4 Adverse Events (CTCAE) will be documented
12. To identify prognostic and predictive features for Allergic reactions (Time Frame - 24 months): Relative frequency of Grade 3 and Grade 4 Adverse Events (CTCAE) will be documented
13. To identify prognostic and predictive features for all other Adverse Events (Time Frame - 24 months): Relative frequency of Grade 3 and Grade 4 Adverse Events (CTCAE) will be documented
14. To investigate the effect of dose density on treatment efficacy of first- and second line therapy (Time Frame - 24 months)
15. To investigate the effect of dose modifications on treatment efficacy of first- and second line therapy (Time Frame - 24 months)
16. To perform a comparative effectiveness analysis of different palliative second line chemotherapy regimens (Time Frame - 24 months)
17. To evaluate treatment behaviours after progression on palliative second line therapy (Time Frame - 24 months)
18. To analyse efficacy of palliative third line therapy (Time Frame - 24 months)
19. To analyse patterns of BRCA testing in real-world practice (Time Frame - 24 months)
20. To analyse the impact of BRCA testing in real-world practice on treatment decisions (Time Frame - 24 months)
21. To analyse the impact of BRCA testing in real-world practice on outcome (Time Frame - 24 months)
22. Prevalence of primary tumor resection in patients with metastatic or locally advanced inoperable pancreatic cancer (Time Frame - 24 months)
23. Prevalence of metastasectomy in patients with metastatic or locally advanced inoperable pancreatic cancer (Time Frame - 24 months)
24. To evaluate the impact of primary tumor resection on outcome (Time Frame - 24 months)
25. To evaluate the impact of metastasectomy on outcome (Time Frame - 24 months)
26. To evaluate the impact of primary granulocyte-colony stimulating factor (G-CSF) use on dose density of FOLFIRINOX (Time Frame - 24 months)
27. To evaluate the impact of primary granulocyte-colony stimulating factor (G-CSF) use on rate of febrile neutropenia (Time Frame - 24 months)
28. To evaluate the impact of primary granulocyte-colony stimulating factor (G-CSF) use on overall outcome (Time Frame - 24 months)
29. To evaluate patterns of molecular profiling in the real world treatment practice of advanced pancreatic cancer (Time Frame - 24 months)
30. To evaluate patterns of next generation sequencing (NGS) in the real world treatment practice of advanced pancreatic cancer (Time Frame - 24 months)
31. To analyse treatment patterns and outcome in the subgroup of very young (<40 years old) patients with advanced pancreatic cancer (Time Frame - 24 months)
32. To analyse treatment patterns and outcome in the subgroup of very old (>75 years old) patients with advanced pancreatic cancer (Time Frame - 24 months)
33. To investigate the impact of diabetes mellitus on treatment efficacy of palliative chemotherapy and disease outcome (Time Frame - 24 months)
34. To investigate the impact of antidiabetic therapy on treatment efficacy of palliative chemotherapy and disease outcome (Time Frame - 24 months)
35. To analyze the mutational landscape of advanced pancreatic cancer and its impact on treatment decision making and clinical outcome (Time Frame - 24 months)
